Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$2.31 +4.5%	$2.13	$0.98 ▼ $3.44	$89.10M	0.17	32,034 shs	6,512 shs
FLXN Flexion Therapeutics	$25.03 +0.3%	$9.20	$4.30 ▼ $13.66	$1.26B	1.53	1.18 million shs	1 shs
ONCT Oncternal Therapeutics	$0.53	$0.53	$0.53 ▼ $7.77	$1.56M	1.18	90,502 shs	N/A
SYRS Syros Pharmaceuticals	$0.00 -84.7%	$0.03	$0.00 ▼ $6.93	$72K	1.31	8.06 million shs	216,581 shs
URGN Urogen Pharma	$13.81 +0.7%	$9.82	$3.42 ▼ $18.15	$632.13M	1.02	1.08 million shs	1.58 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	+4.52%	+0.87%	+4.52%	+111.93%	-0.43%
FLXN Flexion Therapeutics	-0.18%	+173.52%	+173.52%	+173.52%	+173.52%
ONCT Oncternal Therapeutics	0.00%	0.00%	0.00%	0.00%	-92.71%
SYRS Syros Pharmaceuticals	-84.66%	-89.02%	-89.20%	-89.20%	-99.95%
URGN Urogen Pharma	+0.73%	+6.56%	+96.72%	+47.07%	-17.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCT Oncternal Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	4.3246 of 5 stars	3.1	5.0	0.0	4.3	1.1	2.5	0.6
URGN Urogen Pharma	4.5377 of 5 stars	4.5	2.0	0.0	4.5	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	0.00	N/A	N/A	N/A
FLXN Flexion Therapeutics	0.00	N/A	N/A	N/A
ONCT Oncternal Therapeutics	2.25	Hold	$10.00	1,798.97% Upside
SYRS Syros Pharmaceuticals	2.20	Hold	$3.33	123,356.79% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	137.92% Upside

Current Analyst Ratings Breakdown

Latest URGN, SYRS, BYSI, FLXN, and ONCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/3/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$36.00 ➝ $10.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	N/A	N/A	N/A	N/A	($0.37) per share	N/A
FLXN Flexion Therapeutics	$85.55M	14.72	N/A	N/A	($0.34) per share	-73.61
ONCT Oncternal Therapeutics	$790K	1.97	N/A	N/A	$10.19 per share	0.05
SYRS Syros Pharmaceuticals	$386K	0.19	N/A	N/A	$0.79 per share	0.00
URGN Urogen Pharma	$90.40M	7.04	N/A	N/A	($0.21) per share	-65.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	-$113.71M	-$2.01	N/A	N/A	N/A	-100.32%	N/A	-44.26%	N/A
ONCT Oncternal Therapeutics	-$39.48M	-$11.69	N/A	N/A	N/A	-1,599.95%	-177.58%	-131.30%	N/A
SYRS Syros Pharmaceuticals	-$164.57M	-$3.03	N/A	N/A	N/A	N/A	-3,369.56%	-97.04%	7/29/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)

Latest URGN, SYRS, BYSI, FLXN, and ONCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	BYSI BeyondSpring	N/A	-$0.06	N/A	$0.11	N/A	N/A
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCT Oncternal Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	2.49	2.49
FLXN Flexion Therapeutics	N/A	4.38	4.05
ONCT Oncternal Therapeutics	N/A	2.39	2.39
SYRS Syros Pharmaceuticals	N/A	2.25	2.25
URGN Urogen Pharma	N/A	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
FLXN Flexion Therapeutics	90.01%
ONCT Oncternal Therapeutics	16.05%
SYRS Syros Pharmaceuticals	91.47%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
FLXN Flexion Therapeutics	9.13%
ONCT Oncternal Therapeutics	11.20%
SYRS Syros Pharmaceuticals	12.26%
URGN Urogen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	80	40.32 million	28.50 million	Optionable
FLXN Flexion Therapeutics	257	50.32 million	45.73 million	No Data
ONCT Oncternal Therapeutics	30	2.96 million	2.63 million	No Data
SYRS Syros Pharmaceuticals	120	26.83 million	23.54 million	Optionable
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable

URGN, SYRS, BYSI, FLXN, and ONCT Headlines

Recent News About These Companies

Urogen Pharma (NASDAQ:URGN) Receives "Buy" Rating from HC Wainwright

July 8 at 8:20 AM | marketbeat.com

UroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA Approvals

July 8 at 6:30 AM | tipranks.com

Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital

July 8 at 3:51 AM | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral Capital

July 7 at 11:38 AM | marketbeat.com

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

July 7 at 8:00 AM | globenewswire.com

UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer

July 6, 2025 | msn.com

Harel Insurance Investments & Financial Services Ltd. Cuts Position in Urogen Pharma (NASDAQ:URGN)

July 4, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

July 2, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

July 1, 2025 | globenewswire.com

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for Information

June 30, 2025 | globenewswire.com

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 30, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 27, 2025 | prnewswire.com

Urogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?

June 24, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by Brokerages

June 24, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 23, 2025 | globenewswire.com

Lowey Dannenberg Notifies UroGen Pharma Ltd. (â€œUroGenâ€ or the â€œCompanyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

June 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 22, 2025 | prnewswire.com

Stocks With Rising Relative Price Strength: UroGen Pharma

June 20, 2025 | msn.com

Urogen Pharma (NASDAQ:URGN) Trading 10.3% Higher - Here's What Happened

June 18, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 18, 2025 | globenewswire.com

HC Wainwright Decreases Earnings Estimates for Urogen Pharma

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN, SYRS, BYSI, FLXN, and ONCT Company Descriptions

BeyondSpring NASDAQ:BYSI

$2.31 +0.10 (+4.52%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$2.26 -0.05 (-2.34%)

As of 07:00 AM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Flexion Therapeutics NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Oncternal Therapeutics NASDAQ:ONCT

$0.53 0.00 (0.00%)

As of 04/29/2025

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Syros Pharmaceuticals NASDAQ:SYRS

$0.0027 -0.01 (-84.66%)

As of 07/9/2025 03:59 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Urogen Pharma NASDAQ:URGN

$13.81 +0.10 (+0.73%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$13.82 +0.01 (+0.07%)

As of 07:03 AM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time